Tumors targeted with cellular immunotherapy can exhibit an "immune escape" phenotype, potentially rendering immunotherapeutic interventions ineffective. As one of the underlying mechanisms, a variety of oncogenes have been shown to interfere with antigen processing and presentation. 1 The epidermal growth factor receptor (EGFR) family, consisting of four closely related transmembrane tyrosine kinase receptors (EGFR1-4 also known as HER1-4), is particularly important for the etiology of carcinomas and represents an attractive target for immunotherapy. HER receptors undergo homo-or heterodimerization and autophosphorylation in response to the binding of small peptide ligands, which activate downstream signaling pathways. The HER2/HER3 dimer is the most active HER signaling dimer, and is critical for signaling in HER2-overexpressing tumors. 2 We and others have reported that HER2 signaling can lead to the downregulation of MHC Class I molecules and impair MHC Class I-restricted recognition by CTLs. [3] [4] [5] This is particularly relevant for therapies targeting breast carcinomas, which frequently overexpressed HER2 together with other members of the EGFR family. We recently The HER2-induced loss of MHC Class I expression and the resultant decrease in CTL sensitivity have important implications for cancer immunotherapy. One potential approach to circumvent this issue would be to pre-select breast cancer patients with tumors that express low or intermediate levels of HER2 for CTLbased immunotherapy, excluding patients with high HER2 and low MHC Class I expression. At least theoretically, this selection would be of particular importance for patients undergoing vaccination with MHC Class I-restricted CTL epitopes. Benavides et al. 6 reported that patients expressing low levels of HER2 (IHC score: 0 or 1+) respond better to vaccination with the HER2 E75 peptide CTL epitope than patients overexpressing (IHC score: 2+ or 3+) HER2, which substantiates the premise for patient selection. Therefore, patients with tumors expressing low levels of HER2, representing > 50% of breast cancer cases, may have greater clinical benefit from MHC Class I-restricted immunotherapy approaches in comparison to the patients whose tumors present high levels of HER2.
MHC Class I inhibits tumor cell lysis by natural killer (NK) cells. Therefore, it may be speculated that MHC Class I downregulation by oncogenes could make transformed cells suitable targets for direct NK cell-mediated tumor rejection or by NK cell-mediated antibody dependent cellular cytotoxicity (ADCC). The balance between activating and inhibiting signals is known to regulate NK cell-mediated cytotoxicity. Thus it is particularly interesting to understand whether oncogenes signaling also affects the ligands for activating NK cell receptors.
In a recent study, we investigated how signaling through HER2/HER3 regulates the MHC Class I chains A and B (MICA and MICB) in human breast cancer cell lines. 7 MICA/B are examples of ligands for the activating NK group 2, member D (NKG2D) receptor, which radiation and inhibitors of DNA replication, can induce the upregulation of NKG2DL. 10 We believe, however, that a direct effect on HER2/HER3 is responsible for MICA/B induction in breast cancer cell lines, as inferred from the administration of the ataxia-telangiectasia-mutated (ATM) and ATM and Rad-3-related (ATR) protein kinase inhibitor caffeine. The functional consequences of HER2/HER3 signaling manifested as enhanced NKG2D-MICA/B dependent NK cell-mediated cytotoxicity of breast cancer lines. is expressed not only by NK but also by CD8 + and γδ T cells. 8 While tumor cell lines and primary tumors express the NKG2D ligand (NKG2DL), MICA/B is also expressed-though at lower levelsby some non-malignant cell types. The extent to which oncogenes can regulate NKG2DL expression is not well understood, but the example of the BCR/ABL oncogene, which can induce MICA in chronic myelogenous leukemia (CML) lends credence to these premises. 9 This may relevant for NK cell-mediated tumor surveillance, since tumor cells expressing NKG2DL are often susceptible to killing by NK cells even if they have normal expression of MHC Class I. We tested a number of experimental situations affecting signaling through HER2/ HER3 in breast cancer cell lines, including pharmacological and genetic interference, overexpression by transfection, and treatment with the HER3-specific ligand NRG1, and assessed how these manipulations affected MICA/B expression. We concluded that signaling through the HER2/HER3 complex augments the expression of MICA/B, although it appears that HER3 more than HER2 constitutes the rate-limiting factor in this process. Among the multiple pathways activated by HER2/HER3 signaling, the PI3K-AKT pathway was shown to predominantly regulate MICA/B expression. Genotoxic stress, such as ionizing Figure 1 . A schematic illustration of how her2/her3 signaling might determine whether cancer cells are killed by t cells or NK cells. (A) If her2/her3 signaling is strong, MhC Class I expression is weak, while the expression of MICA/B will be enhanced. In these conditions, the NK cell-mediated killing of tumor cells will dominate, while cancer cells will be relatively resistant to CtL-mediated killing. (B) If her2/her3 signaling is weak, MhC Class I expression will be unaffected, a conditions in which cancer cells can be killed by CtLs.
